Huawei Plans to Expand AI Pharma Development With Domestic Firms as Analysts Warn of Risks
The Chinese state-linked tech giant is transforming from an ‘equipment supplier’ into an ‘industry operating system,’ one analyst said.
Huawei announced plans to expand its artificial intelligence collaboration with Chinese pharmaceutical companies into drug discovery. Analysts warn of risks associated with these moves by the Chinese communist regime-linked technology conglomerate. Huawei’s president of its healthcare business unit stated that collaborations would deepen research into AI in the medical field, leading to more results in drug manufacturing, clinical trials, and implementation.
- Huawei is expanding its AI collaboration with Chinese pharmaceutical companies.
- The expansion includes the drug discovery market.
- Analysts have warned of potential risks to the Chinese public and other nations.
- Huawei’s collaborations aim to deepen research in AI for the medical field.
- The company’s projects are mainly with domestic drugmakers, with existing collaborations in hospitals.
- Huawei is exploring more opportunities in the healthcare sector.
Write a comment